The game-changing HIV drug Lenacapavir will soon be available in NHS England, saving lives across the country. However, concerns remain about access for marginalized communities in the global south who contributed to its development.

The International Aids Conference in Rio de Janeiro revealed that the era of Aids exceptionalism is concluding due to significant funding cuts, despite scientific advancements like lenacapavir, prompting critical questions for the movement's future.

A new injectable drug, Lenacapavir, administered twice a year, offers a significant improvement for HIV prevention in high-risk groups, potentially replacing daily pills. Its long-term effectiveness hinges on its accessibility to those who need it most.

The drug Lenacapavir, administered twice a year and offering over 99% protection against HIV, has been approved and is slated for a large-scale rollout across Southern Africa after years of research and clinical trials.

Benue State launches Lenacapavir, a new twice-yearly injectable drug for HIV prevention, offering a discreet and effective option to fight high prevalence. Read More:…

South Africa is preparing for the imminent roll-out of lenacapavir (LEN), a twice-yearly HIV prevention injection. This development comes amidst concerns about donor defunding impacting HIV efforts.

Nigeria's Federal Capital Territory Administration (FCTA) is introducing Lenacapavir, a new injectable HIV prevention drug, to be administered twice a year to combat new infections.

The new HIV injection, Lenacapavir, faces a slow rollout in Abuja due to limited doses and significant logistical challenges, according to officials.

Initial trials of lenacapavir, an injectable drug nearly equivalent to a vaccine for AIDS, are underway in Africa. Eswatini, with the world's highest HIV prevalence, is among the first countries to distribute the drug, with health authorities hoping it can end the epidemic.

An activist living with HIV argues that the UK's cuts to financial aid represent a betrayal of women and girls in sub-Saharan Africa, especially amidst medical breakthroughs like the HIV prevention drug Lenacapavir that require support.

South Africa is preparing to roll out the twice-a-year lenacapavir HIV prevention shot, with projections indicating a significant reduction in infections by 2045 if implemented swiftly.

Mr Ghebreyesus said a new medicine approved in 2025 for HIV prevention, Lenacapavir, represents the most significant development in combating HIV since the first antiretroviral treatments were…

No recklessness: State clarifies limits of new HIV prevention Lenacapavir  the-star.co.ke

Tanzania has officially registered Lenacapavir, a new drug, marking a significant advancement in the country's efforts for HIV prevention and treatment.

South Africa and Zambia are struggling with the rollout of lenacapavir, a new six-monthly HIV prevention injection, due to limited supplies despite high demand and promising early results.

Lenacapavir, a groundbreaking HIV drug, has not yet been distributed to Latin American countries like Brazil, Mexico, and Peru, despite their participation in clinical trials, leading to calls for patent reform.

Malawi has become one of the latest African countries to launch Lenacapavir, a twice-yearly injectable HIV prevention drug, offering new hope in the fight against HIV.

Lenacapavir, an HIV prevention drug requiring twice-yearly shots, is being introduced in Zambia, a country whose health system has been weakened by cuts in American aid.

A new lenacapavir jab, which removes the burden of daily pills, is being hailed as a "once-in-a-generation" breakthrough in HIV treatment. Experts emphasize the importance of ensuring this innovation reaches young women who need it most to gain control over HIV risk.

South Africa is set to begin rolling out lenacapavir, the world's most potent HIV prevention medication, an injection administered twice a year, though ensuring its uptake remains a challenge.

South Africa has received its first consignment of lenacapavir, a twice-a-year anti-HIV injection, which arrived from Dublin six weeks later than anticipated.

Eswatini, a southern African country with the world's highest HIV prevalence, is receiving insufficient amounts of lenacapavir, a drug that could significantly reduce new HIV infections.

Nigeria's health agency has issued a warning to pregnant women against using the new long-acting Lenacapavir HIV injection, citing insufficient safety data for this demographic.

Nigerians are seeking Lenacapavir, a new anti-HIV injection for prevention. Learn about the high demand, government rollout, and how this PrEP drug works. Read More:…

Every year, millions of people become newly infected with HIV.

Kenya's health authorities have started offering lenacapavir, a long-acting HIV prevention drug administered by injection, free of charge to eligible patients, providing protection for six months.

The highly effective twice-a-year injectable drug lenacapavir, used for HIV prevention, is beginning its distribution, but questions are being raised about its accessibility to the areas most in need.

A new drug called lenacapavir, developed by Gilead Sciences, has shown nearly 100% effectiveness in preventing HIV infection with a twice-a-year injection, now facing the challenge of patient access.

South Africa has become the ninth African country to introduce the new long-acting HIV prevention drug, lenacapavir, which offers protection for up to six months with a single injection.

Benue State, which carries Nigeria's highest HIV treatment burden, has launched Lenacapavir, a long-acting injectable drug for HIV prevention, as part of its strategy to end AIDS by 2030.

Ebonyi State in Nigeria has officially launched Lenacapavir, an injectable medication aimed at preventing HIV transmission. This initiative marks a significant step in the region's public health efforts against HIV.

Kwara State in Nigeria has introduced a free, twice-yearly anti-HIV injection, Lenacapavir, to enhance HIV prevention efforts and reduce new infections among at-risk residents.

The United States and the Global Fund have set a goal to provide lenacapavir, an HIV treatment, to 3 million beneficiaries by 2028. This initiative aims to significantly expand access to critical HIV medication globally.

Eswatini (formerly Swaziland) has begun administering lenacapavir, a breakthrough injectable drug, with health authorities hoping to end the HIV/AIDS epidemic in the country by 2030.

A charity reports that Kenya's rollout of the "breakthrough" HIV prevention drug lenacapavir is failing to reach the most vulnerable populations who need it most.

Nigeria has begun rolling out Lenacapavir, a long-acting injectable drug for HIV prevention, with 52,000 doses arriving as part of its goal to end AIDS by 2030, though the health agency has warned against its use in pregnant women due to insufficient safety data.

Nigeria has taken a major step in its fight against HIV with the arrival of the first tranche of lenacapavir, a long-acting injectable drug expected to transform HIV prevention and accelerate…

Nigeria's Federal Government has confirmed that Lenacapavir, a breakthrough HIV prevention injection, will arrive in March. This twice-yearly PrEP drug has shown 100% effectiveness.

A new study has found that to escape a drug called lenacapavir, HIV has to damage one of its own components, the capsid. The finding reaffirmed the belief that the viral capsid is a good drug target and that the virus can’t afford to change it too much, opening the door to a new generation of drugs